Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Nexalin Technology, Inc. (NXL) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $4.85, with a market capitalisation of $4.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.51 to $60.00. This page covers its latest market performance, valuation, price trends and company information.
$4.14M | |
$4.84 | |
$1,016.40 | |
$4.51 | |
$4.85 | |
-- | |
9.75K | |
-- | |
$60.00 | |
$4.51 | |
-- | |
-- |
Nexalin Technology, Inc. (NXL) is trading at $4.85 in pre-market trading as of 2026-09-16 11:01:00, down 0.02% ($0.00) from the previous close of $4.85
Pre-market trading shows how investors are pricing NXL before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Nexalin Technology, Inc. (NXL) moved from $5.06 to $4.85, representing a decline of 4.17% ($0.21).
The stock traded between $4.51 and $5.49 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 16.75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.6%
NXL is currently trading at $4.85, placing it 0.6% of the way from its 52-week low of $4.51 to its 52-week high of $60.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nexalin Technology, Inc. (NXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.